SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Aurinia Pharmaceuticals Inc. (AUPH) News

Follow Aurinia Pharmaceuticals Inc. (AUPH) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 4 public stories across 3 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol AUPH Asset equity Sector Markets 90 days 1 Last 15.41 Updated Nov 02, 2026, 10:18 AM UTC Open live news feed Open AUPH chart & news
M Aurinia Reports Fiscal Q3 Profit Growth of 35.42% Aurinia reported fiscal 2026 third-quarter profit attributable to shareholders up 35.42% year over year, with basic EPS of 0.78 dollars. EQUITY | Nov 02, 2026, 10:18 AM UTC M Aurinia says Teva generic voclosporin may launch after 2036 Aurinia Pharmaceuticals says Teva may launch a generic version of voclosporin in the U.S. no earlier than December 7, 2036, while patent litigation continues in New Jersey. REGULATION | Aug 19, 2026, 08:06 PM UTC L Aurinia settles U.S. patent litigation with Teva over voclosporin Aurinia Pharmaceuticals says it has settled patent litigation with Teva over generic voclosporin in the U.S. REGULATION | Aug 19, 2026, 08:05 PM UTC L Aurinia Pharmaceuticals Affirms FY2026 Sales Guidance of $315.000M-$325.000M vs $323.065M Est Aurinia Pharmaceuticals (NASDAQ: AUPH ) affirms FY2026 sales outlook from $315.000 million-$325.000 million to $315.000 million-$325.000 million vs $323.065 million estimate. EARNINGS | Aug 06, 2026, 12:41 PM UTC